Adalimumab is a monoclonal antibody that works by blocking TNF-alpha, a protein responsible for inflammation. It is used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. By reducing inflammation, it helps relieve symptoms like joint pain, swelling, and skin lesions, improving the patient’s quality of life.
Dosage:
Rheumatoid & Psoriatic Arthritis: 40 mg every 2 weeks
Ankylosing Spondylitis: 40 mg every 2 weeks
Crohn’s Disease & Ulcerative Colitis: 160 mg on Day 1, then 80 mg on Day 15, followed by 40 mg every 2 weeks
Plaque Psoriasis: 80 mg first dose, then 40 mg every 2 weeks
Adalimumab is contraindicated in patients with severe infections (e.g., active tuberculosis, sepsis), hypersensitivity to the drug, moderate to severe heart failure, and demyelinating disorders (e.g., multiple sclerosis).
Precautions
Adalimumab is contraindicated in patients with severe infections (e.g., active tuberculosis, sepsis), hypersensitivity to the drug, moderate to severe heart failure, and demyelinating disorders (e.g., multiple sclerosis).
Lactation
Only if Necessary
Side Effects
Increased Risk of Infections (TB, Fungal, Bacterial)
Injection Site Reactions (Redness, Swelling, Pain)